HOSTS

German Cancer Research Center (DKFZ)

The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with the Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. DKFZ is a member of the Helmholtz Association of National Research Centers.

Cancer Core Europe (CCE)

Cancer Core Europe (CCE) brings together the Cancer Research UK Cambridge Centre (Cambridge, United Kingdom), the German Cancer Research Center with the National Center for Tumor Diseases (Heidelberg, Germany), the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy), the Karolinska Institutet (Stockholm, Sweden), the Netherlands Cancer Institute (Amsterdam, The Netherlands), and the Vall d’Hebron Institute of Oncology (Barcelona, Spain). Given the excellent track records of the seven participating centers, CCE will be able to support the full spectrum of research required to address the cancer research – cancer care continuum. CCE also constitutes a unique environment for the training of up-and-coming talents in innovative translational and clinical oncology.

ORGANIZED BY

National Center for Tumor Diseases (NCT), Heidelberg

The National Center for Tumor Diseases (NCT) Heidelberg combines patient care and patient-oriented research under one roof. What is special about the NCT is its multidisciplinary approach. Two outstanding institutions in research and patient care, the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital (UKHD), have joined forces in order to provide best patient care. Cancer patients receive state of the art therapy at the NCT. Physicians and scientists from multiple disciplines work side by side to implement new promising research results as fast as possible. All of them follow the core concept of the NCT: Together against cancer – with focus on the patient.

SUPPORTED BY

German Cancer Consortium (DKTK)

The German Cancer Consortium (DKTK) is a long-term, joint initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs) in 2012. The German Cancer Research Center, the consortium’s core center, works together with more than 20 academic research institutions and university hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich and Tübingen to create the best possible conditions for clinical cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research, as well as clinical trials for innovative therapeutic and diagnostic procedures. Another key focus of the consortium’s work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.

Cancer Prevention Europe (CPE)

The mission of Cancer Prevention Europe (CPE), a consortium of organizations across the whole of Europe, is to reduce morbidity and mortality from cancer in European populations through prevention and earlier detection of the disease. This will be accomplished through (1) research to optimize the implementation of known preventive strategies, (2) the dissemination of established best practices in prevention, in order to see innovative research translated into effective cancer prevention guidelines and policies nationally and internationally, and (3) research to identify novel targets for prevention.

Molecular Oncology

Molecular Oncology is an open access journal that primarily publishes Research Articles from the fields of basic, translational, and clinical cancer research. We also consider Review Articles, Commentaries, and Policy Papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Manuscripts are handled by a team of dedicated academic Section Editors under a transparent peer review scheme. Molecular Oncology is owned by the Federation of European Biochemical Societies (FEBS). FEBS is a not-for-profit organization. Any income from the journal will be used to support scientists through fellowships, courses, travel grants, prizes, and other FEBS initiatives. 

ORGANIZING TEAM